Compare BHP Billiton Limited (BHP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Inovio Pharmaceuticals Inc — how do they compare? BHP Billiton Limited trades at $89.96 (market cap $229.15B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: BHP Billiton Limited is far larger — about 2917.3× Inovio Pharmaceuticals Inc's market cap, and BHP Billiton Limited pays a 2.95% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BHP | INO | |
|---|---|---|
Market Cap | $229.15B | $78.55M |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $2.87 |
52-Week Low | $52.14 | $0.66 |
Enterprise Value | $243.35B | $49.56M |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.36, down 0.28% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q4 2025 earnings, missing EPS estimates, while Q2 2025 beat expectations. Revenue for 2024 was $55.66B with a net income margin of 18.97%, though profitability has fluctuated in recent years. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production and revenue streams.
Outlook is cautious due to operational risks from strikes and volatile commodity prices, but strong cash flow and institutional buying support long-term value. Analysts are predominantly neutral with 65% hold ratings, reflecting balanced risk-reward. Key risks include labor disputes and copper output misses, while opportunities lie in AI-driven copper demand growth and cost management.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
